Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

BACKGROUND: Patients with diffuse large B-cell lymphoma treated with first-line anthracycline-based immunochemotherapy and remaining in remission at 2 years have excellent outcomes. This study assessed overall survival (OS) stratified by progression-free survival (PFS) at 24 months (PFS24) using ind...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Maurer, M J, Habermann, T M, Shi, Q, Schmitz, N, Cunningham, D, Pfreundschuh, M, Seymour, J F, Jaeger, U, Haioun, C, Tilly, H, Ghesquieres, H, Merli, F, Ziepert, M, Herbrecht, R, Flament, J, Fu, T, Flowers, C R, Coiffier, B
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096732/
https://ncbi.nlm.nih.gov/pubmed/29897404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy203
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki